In the early 1990's, Pentech was one of the first companies to recognize the need for drugs to treat erectile dysfunction and premature ejaculation and as a result, focused its efforts on the development of products to treat these conditions. During this time, Pentech also explored the development of compounds for the treatment of Female Sexual Dysfunction and Parkinson's Disease.

By 1996, Pentech had developed and conducted early-phase studies on a novel sublingual form of apomorphine hydrochloride which was subsequently licensed to TAP Pharmaceutical Products, Inc. for Phase 3 testing and regulatory submission. This product received marketing authorization from the European Commission in 2001 for first-line treatment of erectile dysfunction and continues to be successfully marketed overseas. For more information regarding this product, you should contact TAP at www.TAP.com.

In the late 1990's amidst increasing concern about the cost of drugs in the United States, Pentech explored the development of cost-effective compounds for the treatment of depression. As a result of this exploration and development work, Pentech reached an agreement with Glaxo-Smith-Kline for the production of the first authorized generic oral paroxetine hydrochloride which is currently distributed in the United States and other countries around the world for Pentech by Par Pharmaceuticals.

Pentech is currently conducting early-stage research and development of therapies for a variety of other medical conditions.

info@pentechinc.com